The role of galenic innovation in improving treatment compliance and persistence: three case studies

References

• StaffordRSWagnerTHLavoriPWNew, but not improved? Incorporating comparative-effectiveness information into FDA labelingN Engl J Med20093611230123319675326
   PubMed Web of Science ®Google Scholar
• StiglitzJEJayadevAMedicine for tomorrow: some alternative proposals to promote socially beneficial research and development in pharmaceuticalsJournal of Generic Medicines20107217226
   Google Scholar
• German Pharmaceutical SocietyBlumeHBrauerKDingermannTon behalf of the expert group “drug innovation”Criteria for the evaluation of drug innovations. Position paperPharmazeutische Zeitung2005150Suppl142 Available at: http://www.dphg.de/includes/upload/DPhG-Positionspapier.pdf. Accessed July 12, 2011. German.
   Google Scholar
• KennedyIAppraising the value of innovation and other benefits a short study for NICE2009 Available from: http://www.nice.org.uk/media/98F/5C/KennedyStudyFinalReport.pdf. Accessed July 5, 2010.
   Google Scholar
• WillisMPerssonUZoellnerYGradlBReducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa[R]) in SwedenAppl Health Econ Health Policy2010837738621043539
   PubMedGoogle Scholar
• AbbottJDoddMBiltonDWebbAKTreatment compliance in adults with cystic fibrosisThorax1994491151208128399
   PubMed Web of Science ®Google Scholar
• GorenoiVSchonermarkMPHagenAInterventions for enhancing medication compliance/adherence with benefits in treatment outcomesGMS Health Technol Assess20083 Doc14.
   Google Scholar
• MarceauCLemiereCBerbicheDPerreaultSBlaisLPersistence, adherence, and effectiveness of combination therapy among adult patients with asthmaJ Allergy Clin Immunol200611857458116950273
   PubMed Web of Science ®Google Scholar
• YangWChangJKahlerKHEvaluation of compliance and health care utilization in patients treated with single pill vs free combination antihypertensivesCurr Med Res Opin2010262065207620629600
   PubMed Web of Science ®Google Scholar
• BrixnerDIYeXChuTCBlumentalsWAHassaneinTITreatment persistence in and cost of therapy for patients with chronic hepatitis C: peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirinAm J Health Syst Pharm2009662171217819966085
   PubMed Web of Science ®Google Scholar
• LareauSCYawnBPImproving adherence with inhaler therapy in COPDInt J Chron Obstruct Pulmon Dis2010540140621191434
   PubMedGoogle Scholar
• ElliottWJImproving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapyJ Clin Hypertens (Greenwich)20091137638219583634
   PubMed Web of Science ®Google Scholar
• RestrepoRDAlvarezMTWittnebelLDMedication adherence issues in patients treated for COPDInt J Chron Obstruct Pulmon Dis2008337138418990964
   PubMedGoogle Scholar
• SirisESSelbyPLSaagKGBorgstromFHeringsRMSilvermanSLImpact of osteoporosis treatment adherence on fracture rates in North America and EuropeAm J Med2009122Suppl 2S3S1319187810
   PubMed Web of Science ®Google Scholar
• BourbeauJBartlettSJPatient adherence in COPDThorax20086383183818728206
   PubMed Web of Science ®Google Scholar
• PriceDRobertsonABullenKRandCHorneRStaudingerHImproved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label studyBMC Pulm Med201010120051135
   PubMed Web of Science ®Google Scholar
• RaboudJLiMWalmsleySOnce daily dosing improves adherence to antiretroviral therapyAIDS Behav2010 [Epub ahead of print].
   Google Scholar
• YentzerBAAdeRAFountainJMSimplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trialCutis20108610310820919606
   PubMed Web of Science ®Google Scholar
• Fosamax SmPCSummary of product characteristics2010 Available from: http://www.medicines.org.uk/EMC/medicine/1175/SPC/Fosamax/#INDICATIONS. Accessed June 15, 2011.
   Google Scholar
• Gelbe Liste PharmindexFosamax2011 Available from: http://www.gelbe-liste.de/pharmindex/praeparat/bi/fosamax-10mg-tbl-msd-sharp-dohme-gmbh/#top. Accessed April 4, 2011.
   Google Scholar
• Fosamax weekly SmPCSummary of product characteristics2010 Available from: http://www.medicines.org.uk/EMC/medicine/4115/SPC/Fosamax+Once+Weekly+70mg+Tablets/#INDICATIONS. Accessed June 15, 2011.
   Google Scholar
• Gelbe Liste Pharmindex [Fosamax once weekly].2011 Available from: http://www.gelbe-liste.de/pharmindex/praeparat/bi/fosamax-einmal-woechentlich-70mg-tbl-msd-sharp-dohme-gmbh/. Accessed April 4, 2011. Password-protected – access restricted to registered health care professionals.
   Google Scholar
• Concerta 18–36 mg SmPCSummary of product characteristics2010 Available from: http://www.medicines.org.uk/EMC/medicine/8382/SPC/Concerta+XL+18+mg+-+36+mg+prolonged+release+tablets/. Accessed June 15, 2011.
   Google Scholar
• Concerta 27 mg SmPCSummary of product characteristics2010 Available from: http://www.medicines.org.uk/EMC/medicine/19549/SPC/Concerta+XL+27+mg+prolonged-release+tablets/#INDICATIONS. Accessed June 15, 2011.
   Google Scholar
• Ritalin SmPCSummary of product characteristics2010 Available from: http://www.medicines.org.uk/EMC/medicine/1316/SPC/Ritalin/#FORM. Accessed January 24, 2011.
   Google Scholar
• Desferal SmPCSummary of product characteristics2010 Available from: http://www.medicines.org.uk/EMC/medicine/2666/SPC/Desferal+Vials%2c+500mg+or+2g/#FORM. Accessed June 15, 2011.
   Google Scholar
• Exjade SmPCSummary of product characteristics2011 Available from: http://www.medicines.org.uk/EMC/medicine/18805/SPC/EXJADE+125+mg%2c+250mg%2c+500mg+dispersible+tablets/#FORM. Accessed June 15, 2011.
   Google Scholar
• Gelbe Liste PharmindexExjade2011 Available from: http://www.gelbe-liste.de/pharmindex/praeparat/bi/exjade-125-mg-tabletten-zur-herstellung-einer-suspension-zum-einnehmen-novartis-pharma-gmbh/. Accessed April 4, 2011.
   Google Scholar
• CramerJARoyABurrellAMedication compliance and persistence: terminology and definitionsValue Health200811444718237359
   PubMed Web of Science ®Google Scholar
• MerkelRLJrKuchibhatlaASafety of stimulant treatment in attention deficit hyperactivity disorder: part IExpert Opin Drug Saf2009865566819785509
   PubMed Web of Science ®Google Scholar
• PorterJBAthanasiou-MetaxaMBowenDKImproved patient satisfaction, adherence and health-related quality of life with deferasirox (Exjade®) in beta-thalassemia patients previously receiving other iron chelation therapiesBlood2009114980981
   Web of Science ®Google Scholar
• YamashitaRSobotaATrachtenbergFThe impact of the child with thalassemia on the family: parental assessment by child health questionnaireBlood2009114558
   Web of Science ®Google Scholar
• MednickLYuSTrachtenbergFSymptoms of anxiety and depression among teens and adults in the thalassemia longitudinal cohort studyBlood200911423123219589929
   PubMed Web of Science ®Google Scholar
• PorterJBBowdenDGanserASatisfaction and adherence significantly improves in patients with beta-thalassemia and myelodysplastic syndromes treated with deferasiroxBlood2008112472
   Web of Science ®Google Scholar
• VichinskyEPakbazZOnyekwereOPatient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trialActa Haematol200811913314118408362
   PubMed Web of Science ®Google Scholar
• OsborneRHDe AbreuLRDaltonAQuality of life related to oral versus subcutaneous iron chelation: a time trade-off studyValue Health20071045145617970927
   PubMed Web of Science ®Google Scholar
• CappelliniMDBejaouiMAgaogluLProspective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemiaClin Ther20072990991717697909
   PubMed Web of Science ®Google Scholar
• DeleaTESofryginOThomasSKBaladiJFPhatakPDCoatesTDCost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspectivePharmacoeconomics20072532934217402805
   PubMed Web of Science ®Google Scholar
• RofailDAbetzLVialaMGaitCBaladiJFPayneKSatisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed patient instrumentValue Health20091210911718637142
   PubMed Web of Science ®Google Scholar
• BockOFelsenbergDBisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practiceClin Interv Aging2008327929718686751
   PubMed Web of Science ®Google Scholar
• KendlerDKungAWFuleihanGPatients with osteoporosis prefer once weekly to once daily dosing with alendronateMaturitas20044824325115207890
   PubMed Web of Science ®Google Scholar
• SimonJALewieckiEMSmithMEPetruschkeRAWangLPalmisanoJJPatient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover studyClin Ther2002241871188612501880
   PubMed Web of Science ®Google Scholar
• CramerJAAmonkarMMHebbornAAltmanRCompliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosisCurr Med Res Opin2005211453146016197664
   PubMed Web of Science ®Google Scholar
• HoarePRemschmidtHMedoriR12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPHEur Child Adolesc Psychiatry20051430530916220214
   PubMed Web of Science ®Google Scholar
• RemschmidtHHoarePEttrichCSymptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label studyEur Child Adolesc Psychiatry20051429730416220213
   PubMed Web of Science ®Google Scholar
• ChouWJChouMCTzangRFBetter efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypesPsychiatry Clin Neurosci20096316717519335386
   PubMed Web of Science ®Google Scholar
• BiedermanJMickEOSurmanCComparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorderBMC Psychiatry200774917868455
   PubMed Web of Science ®Google Scholar
• SteeleMWeissMSwansonJWangJPrinzoRSBinderCEA randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorderCan J Clin Pharmacol200613e50e6216456216
   PubMedGoogle Scholar
• VichinskyEOnyekwereOPorterJA randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell diseaseBr J Haematol200713650150817233848
   PubMed Web of Science ®Google Scholar
• PigaAGalanelloRForniGLRandomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overloadHaematologica20069187388016818273
   PubMed Web of Science ®Google Scholar
• LuckeyMMGilchristNBoneHGTherapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosisObstet Gynecol200310171172112681875
   PubMed Web of Science ®Google Scholar
• SchnitzerTBoneHGCrepaldiGTherapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate once-weekly study groupAging (Milano)20001211210746426
   PubMedGoogle Scholar
• UchidaSTaniguchiTShimizuTTherapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized studyJ Bone Miner Metab20052338238816133688
   PubMed Web of Science ®Google Scholar